Dual-Targeting Nanobody Therapy for Immunological Disorders: Harnessing ORAI1 and PDCD1 Inhibition
VHH-P523 is a bispecific, humanized nanobody-based antibody engineered to simultaneously target ORAI calcium release-activated calcium modulator 1 (ORAI1) and programmed cell death 1 (PDCD1). Currently in the Biological Testing stage of development, VHH-P523 is designed for the potential treatment of immunological disorders. By leveraging advanced antibody engineering, this therapeutic combines high specificity for both ORAI1 and PDCD1, offering a novel approach for modulating immune responses in a range of immune-mediated diseases. VHH-P523 represents a promising candidate in the expanding landscape of targeted biologics for immunological conditions.
| Candidate | VHH-P523 |
| Target | ORAI calcium release-activated calcium modulator 1 (ORAI1) programmed cell death 1 (PDCD1) |
| Modality | humanized bispecific VHH |
| Indication | Immunological Disorders |
Licensing Opportunity
VHH-P523 is available for out-licensing and collaborative development partnerships. We welcome inquiries from biopharmaceutical companies and research organizations seeking to advance innovative therapies in immunological disorders.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P523 |
Modality
VHH-P523 is a bispecific antibody modality that integrates a human monoclonal IgG2 lambda backbone targeting ORAI1, with two single-domain nanobodies directed at PDCD1 fused to its C-terminus. This structural design, produced in Chinese hamster ovary cells, combines the robust effector functions and extended half-life of the IgG2 framework with the unique properties of nanobodies, such as small size, high tissue penetration, and exceptional stability. These attributes are particularly advantageous for treating immunological disorders, as they allow improved tissue access, enhanced targeting of immune cells, and potentially superior blockade of pathogenic immune signaling.
Target
ORAI1 and PDCD1 are critical regulators of immune cell function. ORAI1 is a membrane calcium channel subunit mediating store-operated calcium entry, essential for lymphocyte activation and cytokine production. PDCD1, an immune checkpoint receptor primarily expressed on activated T cells and other immune subsets, plays a key inhibitory role in immune regulation. ORAI1 is prominent in T lymphocytes, while PDCD1 is expressed broadly on effector T cells and exhausted T cell populations. Both ORAI1 and PDCD1 are validated therapeutic targets in immunological disorders due to their involvement in autoimmunity and chronic inflammatory pathology. Dual targeting of ORAI1 and PDCD1 with VHH-P523 strategically addresses pathogenic immune overactivation and dysfunctional immune tolerance, positioning it as a highly attractive and differentiated asset in immune therapeutics.
Mechanism of Action
VHH-P523 acts via simultaneous blockade of ORAI1 and PDCD1. By binding ORAI1, the antibody inhibits store-operated calcium influx, modulating T cell activation and subsequent cytokine response. Concurrently, targeting PDCD1 interferes with immune checkpoint signaling, relieving T cell suppression and enhancing anti-pathogenic immune activity. This dual mechanism leverages immune checkpoint inhibition and calcium channel blockade to rebalance immune responses in immunological disorders. The nanobody-based platform underpinning VHH-P523 supports formats such as bispecifics and antibody-drug conjugates, expanding its potential for tailored immune modulation across diverse disease contexts.
Immunological Disorders
Immunological disorders encompass a wide spectrum of diseases characterized by abnormal immune responses, including autoimmune conditions, chronic inflammation, and immune deficiencies. These disorders exert a significant global health burden, affecting millions of individuals and often resulting in chronic morbidity. Standard treatment strategies include immunosuppressants, corticosteroids, and targeted biologics, yet many patients experience inadequate disease control, adverse effects, or relapse. Limitations in efficacy, specificity, and safety underline the urgent need for novel therapeutics. VHH-P523, by targeting both ORAI1 and PDCD1, offers a next-generation approach aimed at precisely regulating immune cell function and restoring immune homeostasis. This dual-targeted intervention has the potential to address unmet needs by providing more effective and safer management of diverse immunological disorders.